Cytek Q3 revenue $48M (+19%), organic growth 2%; net loss $6.5M; FY guidance $188-192M

Cytek Biosciences, Inc.

Total revenue $48.0M (+19% YoY); organic revenue $41.2M (+2%); acquired Luminex contributed $6.8M.
Gross profit margin 57% vs 66% prior year; adjusted gross margin 59% vs 68%.
Operating loss $6.4M vs income $1.4M; net loss $6.5M vs net income $1.6M; adjusted EBITDA $3.7M vs $7.3M.
FY 2023 revenue guidance $188-192M (15-17% growth); organic expected flat vs 2022.
Repurchased 1,155,229 shares at $8.4M; cash $288M, down from $344M at Dec 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Cytek Biosciences, Inc. reported the third quarter ended September 30, 2023 results: revenue $48.0 million.

Period: the third quarter ended September 30, 2023
Revenue: $48.0 million
Result: reported results

Exact text from the filing

Total revenue for the third quarter of 2023 was $48.0 million

View on SEC.gov

Browse all earnings releases →

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-272504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.